Jeff Bezos-backed Prometheus has raised $12 billion in new funding and is now valued at $41 billion, according to TechCrunch, as the startup pushes to build what it calls an “artificial general engineer” for the physical world. The company is aiming to use physical AI to automate heavy engineering and drug design, two areas that could have broad industrial and scientific impact.
The funding round is notable not only for its size but also for the ambition behind it. Rather than focusing on a single robot or narrow automation task, Prometheus is positioning itself around models and systems that can reason about and operate in real-world environments, a direction that reflects the wider surge of interest in physical AI. That field includes companies trying to train machines to work outside software-only settings, from robotics and logistics to simulation and autonomous systems.
TechCrunch reports that Prometheus wants to develop tools that can help machines handle complex engineering work in the physical world. That puts it in the same broader conversation as other startups trying to close the gap between digital intelligence and real-world action, including firms building simulation platforms and robotics data systems to make robot behavior more reliable in unpredictable environments.
The scale of the new investment also signals how aggressively investors are backing the next wave of AI infrastructure. A $41 billion valuation places Prometheus among the most highly valued startups in the sector, even though the company’s long-term goals remain highly technical and still largely unproven at full scale. For now, the promise is that a system capable of understanding physics, materials, and engineering constraints could accelerate work in industries where mistakes are costly and automation has been difficult to deploy.
The biggest question is how quickly that vision can move from research and prototypes to practical use. If Prometheus succeeds, its technology could affect everything from manufacturing and infrastructure to pharmaceutical discovery. If it falls short, the round will still stand as another example of how much capital is flowing into AI companies trying to extend machine intelligence beyond screens and into the physical world.